Cambrex Corporation (NYSE:CBM) Receiving Somewhat Favorable Media Coverage, Report Finds

News stories about Cambrex Corporation (NYSE:CBM) have been trending somewhat positive on Friday, Accern Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cambrex Corporation earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 10 out of 100, meaning that recent press coverage is extremely unlikely to have an effect on the company’s share price in the near term.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:

Several brokerages recently weighed in on CBM. BidaskClub raised Cambrex Corporation from a “hold” rating to a “buy” rating in a report on Friday, August 4th. Zacks Investment Research downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Finally, ValuEngine downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $64.00.

Shares of Cambrex Corporation (NYSE CBM) traded down 0.85% on Friday, reaching $52.80. The company’s stock had a trading volume of 191,728 shares. The company’s 50-day moving average is $58.69 and its 200 day moving average is $55.48. Cambrex Corporation has a 12-month low of $38.30 and a 12-month high of $62.95. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of 19.23 and a beta of 2.28.

Cambrex Corporation (NYSE:CBM) last issued its quarterly earnings results on Friday, August 4th. The biotechnology company reported $0.76 EPS for the quarter, hitting analysts’ consensus estimates of $0.76. The business had revenue of $134.55 million during the quarter, compared to analysts’ expectations of $136.82 million. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The business’s quarterly revenue was up 13.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.68 earnings per share. Equities analysts anticipate that Cambrex Corporation will post $3.08 earnings per share for the current fiscal year.

In related news, Director Leon J. Hendrix, Jr. sold 20,656 shares of the stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $55.95, for a total transaction of $1,155,703.20. Following the completion of the sale, the director now owns 74,662 shares in the company, valued at $4,177,338.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Steven M. Klosk sold 12,000 shares of the stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $61.39, for a total value of $736,680.00. Following the sale, the chief executive officer now owns 95,328 shares of the company’s stock, valued at approximately $5,852,185.92. The disclosure for this sale can be found here. In the last 90 days, insiders sold 70,656 shares of company stock valued at $4,064,423. Company insiders own 2.48% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Cambrex Corporation (NYSE:CBM) Receiving Somewhat Favorable Media Coverage, Report Finds” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.com-unik.info/2017/08/11/cambrex-corporation-nysecbm-given-media-impact-rating-of-0-10-updated-updated-updated.html.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Insider Buying and Selling by Quarter for Cambrex Corporation (NYSE:CBM)

What are top analysts saying about Cambrex Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cambrex Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit